Plasma Fractionation Market Size, Share, Analysis & Growth...

Plasma Fractionation Market Size, Share, Analysis & Growth Report 2025

Postado 2025-05-09 10:10:35

IMARC Group, a leading market research company, has recently released a report titled “Plasma Fractionation Market Report by Product (Immunoglobulins, Albumin, Coagulation factor VIII, Coagulation factor IX), Sector (Private Sector, Public Sector), Application (Neurology, Immunology, Hematology, and Others), End User (Hospitals and Clinics, Clinical Research Laboratories, Academic Institutes), and Region 2025-2033”. The study provides a detailed analysis of the industry, including the plasma fractionation market trends, share, size, and industry growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

The global plasma fractionation market size reached USD 26.4 Billion in 2024. Looking forward, the market is expected to reach USD 41.4 Billion by 2033, exhibiting a growth rate (CAGR) of 4.86% during 2025-2033.

Request to Get the Sample Report:

https://www.imarcgroup.com/plasma-fractionation-market/requestsample

Plasma Fractionation Market Trends

The plasma fractionation market is poised for significant growth, reflecting the increasing demand for plasma-derived therapies and advancements in technology. As healthcare providers continue to emphasize the importance of immunoglobulins and clotting factors in treating various medical conditions, the market is expected to expand rapidly. By 2025, we will likely see a surge in the development and approval of new plasma-derived products, driven by ongoing research and regulatory support.

Additionally, the integration of advanced fractionation technologies will enhance the efficiency and safety of production processes, making these therapies more accessible to patients in need. The rising prevalence of chronic diseases and the aging population will further contribute to the demand for plasma fractionation products, as healthcare systems seek effective treatment options. Overall, the plasma fractionation market is characterized by innovation, increased investment, and a commitment to meeting the evolving healthcare needs of diverse patient populations.

Market Dynamics in the Plasma Fractionation Market

Increasing Demand for Immunoglobulins and Clotting Factors

The plasma fractionation market is experiencing substantial growth, primarily driven by the rising demand for immunoglobulins and clotting factors. As the prevalence of immunodeficiency disorders and bleeding disorders continues to rise globally, healthcare providers are increasingly relying on plasma-derived products for treatment. By 2025, it is projected that the demand for immunoglobulin therapies will escalate, particularly as awareness of autoimmune diseases and hereditary conditions grows.

Additionally, advancements in treatment protocols and the introduction of new therapies utilizing immunoglobulins and clotting factors are expected to further propel market growth. The increasing number of patients requiring these therapies, coupled with an aging population more susceptible to chronic diseases, will drive the demand for plasma fractionation products. Manufacturers are thus focusing on enhancing production capabilities and ensuring a consistent supply of high-quality plasma-derived products to meet this growing need.

Technological Advancements in Plasma Fractionation Techniques

Technological innovations are significantly influencing the plasma fractionation market, leading to improved efficiency and yield in the extraction of plasma proteins. By 2025, we can expect to see the adoption of advanced fractionation technologies, such as chromatography and membrane filtration, which enhance the separation and purification processes. These advancements not only increase the yield of valuable plasma proteins but also improve the overall quality and safety of the end products.

Moreover, automation and digitalization in manufacturing processes are streamlining operations, reducing costs, and minimizing the risk of contamination. As a result, manufacturers can produce plasma-derived therapies more efficiently, making them more accessible to healthcare providers and patients. The focus on innovation in plasma fractionation technologies is expected to drive competition among companies, leading to a more robust and dynamic market landscape.

Growing Regulatory Support and Investment in Research

The plasma fractionation market is benefiting from increased regulatory support and investment in research and development, which are crucial for advancing product safety and efficacy. By 2025, regulatory agencies are likely to implement more streamlined approval processes for plasma-derived therapies, encouraging innovation and expediting the introduction of new products into the market.

Furthermore, increased funding from both public and private sectors for research initiatives focused on plasma fractionation technologies is expected to accelerate the development of novel therapies. This influx of investment will enable companies to explore new applications for plasma-derived products, such as in regenerative medicine and personalized therapies. As the market expands, collaboration among stakeholders, including academic institutions, research organizations, and industry players, will play a vital role in fostering innovation and ensuring that the plasma fractionation market continues to evolve in response to emerging healthcare needs.

Plasma Fractionation Market Report Segmentation:

Breakup by Product:

Immunoglobulins
Albumin
Coagulation factor VIII
Coagulation factor IX

Breakup by Sector:

Private Sector
Public Sector

Breakup by Application:

Neurology
Immunology
Hematology
Other Applications

Breakup by End User:

Hospitals and Clinics
Clinical Research Laboratories
Academic Institutes

Breakup by Region:

· North America

· Asia-Pacific

· Europe

· Latin America

· Middle East and Africa

Competitive Landscape with Key Players:

The competitive landscape of the plasma fractionation market size has been studied in the report with the detailed profiles of the key players operating in the market.

Some of These Key Players Include:

ADMA Biologics
Bio Products Laboratory Ltd.
Boccard
Grifols, S.A.
Hemarus Therapeutics Limited
Intas Pharmaceuticals Limited
LFB S.A.
Merck Group
Octapharma AG
PlasmaGen BioSciences Pvt. Ltd.
SK Plasma Co. Ltd.
Virchow Biotech Private Limited

Ask Analyst for Customized Report:

https://www.imarcgroup.com/request?type=report&id=5973&flag=C

Key Highlights of the Report:

· Market Performance (2019-2024)

· Market Outlook (2025-2033)

· Market Trends

· Market Drivers and Success Factors

· Impact of COVID-19

· Value Chain Analysis

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group

134 N 4th St

Brooklyn, NY 11249, USA

Website: imarcgroup.com

Email: sales@imarcgroup.com

Americas: +1-631-791-1145